Virtus Fund Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Virtus Fund Advisers’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$344K	Buy	+26,948	New	+$396K	﹤0.01%	416

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Virtus Fund Advisers's JNCE Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017: 26,948 shares worth $344K. The stake represents ﹤0.01% of the portfolio and ranks #416 among its holdings.

83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

Virtus Fund Advisers held 26,948 shares of Jounce Therapeutics, Inc. Common Stock worth $344K as of Q4 2017.
Jounce Therapeutics, Inc. Common Stock was a new Virtus Fund Advisers position in Q4 2017.
Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #416 holding.
83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.